FibroGen, Inc (NASDAQ:FGEN) Director Gerald Lema acquired 3,500 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were bought at an average price of $46.70 per share, for a total transaction of $163,450.00. Following the purchase, the director now directly owns 3,500 shares of the company’s stock, valued at $163,450. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

FibroGen, Inc (NASDAQ:FGEN) traded down $0.05 during trading on Tuesday, reaching $44.45. 343,325 shares of the company’s stock traded hands, compared to its average volume of 617,295. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16. FibroGen, Inc has a 12-month low of $19.25 and a 12-month high of $60.15.

A number of institutional investors have recently bought and sold shares of FGEN. FMR LLC grew its position in FibroGen by 96.9% in the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after buying an additional 1,641,423 shares during the last quarter. EcoR1 Capital LLC grew its position in FibroGen by 3,674.1% in the second quarter. EcoR1 Capital LLC now owns 1,585,457 shares of the biopharmaceutical company’s stock worth $51,210,000 after buying an additional 1,543,448 shares during the last quarter. Janus Henderson Group PLC acquired a new position in FibroGen in the second quarter worth approximately $45,633,000. Eagle Asset Management Inc. acquired a new position in FibroGen in the third quarter worth approximately $46,158,000. Finally, Vanguard Group Inc. boosted its stake in FibroGen by 15.1% in the 2nd quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock worth $187,612,000 after purchasing an additional 761,421 shares during the period. Hedge funds and other institutional investors own 57.42% of the company’s stock.

A number of research analysts recently commented on FGEN shares. Jefferies Group reiterated a “buy” rating and set a $75.00 price objective on shares of FibroGen in a research note on Tuesday, September 12th. Mizuho restated a “hold” rating and issued a $61.00 price target on shares of FibroGen in a research report on Thursday, November 9th. Stifel Nicolaus restated a “buy” rating and issued a $80.00 price target on shares of FibroGen in a research report on Thursday, September 14th. ValuEngine lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Citigroup lifted their price target on shares of FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $65.67.

COPYRIGHT VIOLATION NOTICE: “Insider Buying: FibroGen, Inc (FGEN) Director Acquires 3,500 Shares of Stock” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/05/insider-buying-fibrogen-inc-fgen-director-acquires-3500-shares-of-stock.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.